The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Overview of the Spanish GETNE-TRASGU study
Rocio Garcia-Carbonero, MD, PhD, of the University Hospital of 12 de Octubre, Madrid, Spain, discusses the recent work of the Spanish Group of NET’s (GETNE) registry in identifying prognostic variables for PFS in stage IV unresectable gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues. Dr Garcia-Carbonero speaks at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, providing an overview of the GETNE-TRASGU study. Five key variables for predictive factors, such as tumor burden and size were identified, allowing NET patients to be classified into prognostic groups. Dr Garcia-Carbonero believes these findings will be of great value to physicians and aid decision making in NET treatment with somatostatin analogues.
